Global Regulatory Affairs Strategy Team Works With Scientific Affairs To Optimize Alternate Drug Development Solutions For Phase III Trial
Global Regulatory Affairs Strategy Team Works With Scientific Affairs To Optimize Alternate Drug Development Solutions For Phase III Trial
1 PagesCLINICAL DEVELOPMENT SERVICES CASE STUDY Global Regulatory Affairs Strategy Team Works with Scientific Affairs to Optimize Alternate Drug Development Solutions for Phase III Trial Situation A small Japanese biopharmaceutical company was looking to expand the indications of a compound, currently approved in Japan for radiation-induced neutropenia, to cervical cancer. The company conducted Phase II and Phase III trials in cervical cancer, but
